Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
3455
Inomata M, Saijo N, Kawashima K, Kaneko A, Fujiwara Y, Kunikane H, Tanaka Y
Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.J Cancer Res Clin Oncol
1995
121:729-38
PubMed ID: 7499444
DOI: 10.1007/BF01213319
901
M Inomata, A Kaneko, N Saijo, S Tokura
Culture of retinoblastoma cells from clinical specimens: growth-promoting effect of 2-mercaptoethanolJ Cancer Res Clin Oncol
1994
120(3):149-55
PubMed ID: 8263010
DOI: 10.1007/BF01202193
13207
Togashi K, Okada M, Suzuki S, Sanomachi T, Seino S, Yamamoto M, Yamashita H, Kitanaka C.
Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway.Anticancer Res
2020
PubMed ID: 32878784
DOI: 10.21873/anticanres.14499